Cell Signaling Technology

Product Pathways - Growth Factors/Cytokines

Rat Vascular Endothelial Growth Factor-164 (rVEGF164 ) #5874

No. Size Price
5874SC 10 µg ( With Carrier ) ¥2,644.00 现货查询 购买询价 防伪查询
5874SF 10 µg ( Carrier Free ) ¥2,644.00 现货查询 购买询价 防伪查询
5874 carrier free & custom formulation / quantityemail request
Applications Dilution Species-Reactivity Sensitivity MW (kDa) Isotype

Species cross-reactivity is determined by western blot.

Applications Key:

Source / Purification

Recombinant rat VEGF164 (rVEGF164) Ala27-Arg190 (Accession #NP_001103803) was expressed in human 293 cells at Cell Signaling Technology.

Cell Signaling Technology在人293细胞中表达生产重组大鼠鼠蛋白VEGF164 (rVEGF164) Ala27-Arg190 (Accession #NP_001103803)。

Molecular Characterization

Recombinant rVEGF164 contains no "tags" and the nonglycosylated protein has a calculated MW of 19,234. DTT-reduced protein migrates as a 24-31 kDa polypeptide. Lower mobility in SDS-PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 46-53 kDa protein. The expected amino-terminal APTTE of recombinant rVEGF164 was verified by amino acid sequencing.

重组的rVEGF164蛋白不包含标签,没有糖基化的蛋白分子量据推算为19,234Da。DTT-还原的蛋白迁移时是作为一个24-31 kDa 的多肽而转移。在SDS-PAGE中的低迁移率是由于其糖基化的作用。未经还原的胱氨酸连接的同型二聚体迁移时作为46-53 kDa 的蛋白而迁移。重组rVEGF164蛋白的N-末端APTTE序列通过测序得到。


>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant rVEGF164. All lots are greater than 98% pure.

6 μg 还原 (+) 和 非还原的(-) hVEGF164通过SDS-PAGE检测,纯度大于98%,所有批次的纯度均高于98%。


The bioactivity of recombinant rVEGF164 was determined in a cell proliferation assay using HUVEC. The ED50 of each lot is between 1-5 ng/ml.

重组蛋白rVEGF164 的生物活性是同过HUVEC的细胞增殖实验确定的。每个批次的ED50在1-5 ng/ml之间。

Coomassie Gel

Coomassie Gel

The purity of recombinant rVEGF164 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant rVEGF164 and staining overnight with Coomassie Blue.重组蛋白 rVEGF164 的纯度用6 µg 还原 (+) 和未还原(-)的蛋白走SDS-PAGE 胶来观察。考马斯亮蓝染色过夜。



The proliferation of HUVEC treated with increasing concentrations of rVEGF164 was assessed. After 72-hour treatment with rVEGF164, cells were incubated with a tetrazolium salt and the OD450-OD650 was determined.经过逐渐递增浓度的rVEGF164处理 HUVEC 的细胞增殖实验。在rVEGF164中处理72小时,细胞在四唑盐中孵育并读取OD450 - OD650 的数值。

Western Blotting

Western Blotting

Western blot analysis of extracts from HUVEC, untreated or treated with rVEGF164 for 15 minutes, using Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (upper) or Akt1 (C73H10) Rabbit mAb #2938 (lower).Western免疫印迹。用 Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (上图) 或Akt1 (C73H10) Rabbit mAb #2938 (下图)研究未经处理和用rVEGF164处理15分钟的HUVEC提取液。


Less than 0.01 ng endotoxin/1 μg rVEGF164.

内毒素含量:<0.01 ng 内毒素/1 μg rVEGF164。


With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg rVEGF164. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.

有载体: 每微克hVEGF164蛋白溶解在包含 20 μg BSA的PBS(pH 7.2)溶液中,并通过 0.22 μm 滤膜冻干。

无载体:每微克hVEGF164蛋白溶解在PBS(pH 7.2)溶液中,并通过 0.22 μm 滤膜冻干。


VEGF164 is one of many splice variants of the VEGF-A gene, and is one amino acid shorter than its human counterpart, VEGF165 (1, 2). VEGF164 is produced by a number of cells including endothelial cells, macrophages, and T cells (1, 2). VEGF164 is involved in angiogenesis, vascular endothelial cell survival, growth, migration, and vascular permeability (1,2). Gene expression is induced by hypoxia, inflammatory cytokines, and oncogenes (1, 2). VEGF164 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix (1-3). VEGFR1 and VEGFR2 are the receptor tyrosine kinases for VEGF164 (2). NRP-1 and NRP-2 may function as co-receptors and enhance VEGFR2 signaling (2-3). Binding of VEGF164 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK, and Paxillin (2).

VEGF164是VEGF-A基因众多剪切方式中的一种,并且之比其人源配对物VEGF165少一个氨基酸(1, 2)。能产生VEGF164的细胞有很多,包括内皮细胞,巨噬细胞和T细胞(1, 2)。VEGF164与血管生成,血管内皮细胞的存活,生长,迁移,和血管渗透性等过程有关(1,2)。基因受到缺氧,炎症细胞因子以及原癌基因的诱导而表达(1, 2)。VEGF164结合到硫酸乙酰肝素并保留在细胞表面和细胞外基质(1-3)。VEGFR1 和 VEGFR2是VEGF164的受体酪氨酸激酶(2)。NRP-1和NRP-2作为其共受体并增强VEGFR2的信号(2-3)。VEGF164结合到VEGFR1 和VEGFR2 上导致PI3K/AKT, p38 MAPK, FAK 和 Paxillin的激活(2)。

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.

Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.

用户评论 --- 共 0


我要参与评论 :